Liver steatosis is primarily driven by the transcription factors SREBP1c and ChREBP, which exert synergistic effects on lipogenic gene expression, thereby regulating hepatic DNL and contributing to steatosis in individuals with NAFLD. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.